Leukemia

Lymphocytic
- Relapsed or Refractory CD19+ Precursor B-lymphoblastic Leukemia
  ▼ 10030: A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-lymphoblastic Leukemia

- Relapsed or Refractory ALL
  ▼ 9775: A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

- Chronic lymphocytic leukemia
  ▼ 9008: A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction

Myelogenous
- Relapsed or refractory AML, myelodysplastic syndrome, or Chronic Myelomonocytic Leukemia
  ▼ 10026: A Phase 1 Study of Ipiimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia

- AML with wild-type p53
  10075: A Phase 1B Study of AMG-232 in Combination with Decitabine in Acute Myeloid Leukemia

- AML in complete remission
  9706: Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)

- AML associated with antecedent myeloproliferative disorder
  10147: A Phase II Randomized Study of Topotecan/Carboplatin with or Without Veliparib or Placebo in Advanced Myeloproliferative Disorders and CMML

- AML/ myeloid malignancy with 11q23 rearrangement or NPM1 mutation
  10200: Combination Pinometostat and 5-Azacitidine for the Treatment of Patients with Relapsed / Refractory Acute Myeloid Leukemia, or Newly Diagnosed Patients who are Ineligible for or Unwilling to Undergo Intensive Therapy, who Harbor an 11q23 Rearrangement

- AML with 11q23 or KMT2A (MLL) rearrangement
  * 10212: A Phase 1b/2 Study of Pinometostat in Combination with Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia

- MDS or oligoblastic AML
  **1009**: A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure

- Hematologic Malignancy
  **10014**: A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies

Hematologic Malignancy, NOS

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: 10/11/2018